Last reviewed May 2, 2026·Editorial Board
BPC-157 (Body Protection Compound 157)
Also known as BPC157, Pentadecapeptide BPC 157, PL-14736
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein fragment isolated from human gastric juice, studied primarily for accelerating tissue repair, protecting the gastrointestinal tract, and modulating inflammation.[1]
What BPC-157 actually is
BPC-157 is a stable pentadecapeptide — a chain of 15 amino acids — synthesized to mimic a fragment of body protection compound, a larger protein found naturally in human gastric juice.[1] The compound was first described in the early 1990s by a research group led by Predrag Sikirić at the University of Zagreb, who has authored or co-authored the majority of published BPC-157 research over the subsequent three decades.[2]
Unlike most peptides, BPC-157 appears to retain biological activity after oral administration in animal models — an unusual property attributed to its stability in gastric juice.[2] Subcutaneous injection remains the most extensively studied route.
Mechanism of action
BPC-157 does not bind a single identified receptor. Animal studies point to several converging pathways: upregulation of vascular endothelial growth factor receptor 2 (VEGFR-2), which drives new blood vessel formation;[3] modulation of the nitric oxide system, affecting vascular tone and tissue perfusion;[2] and activation of growth hormone receptors in tendon fibroblasts, which appears to accelerate collagen synthesis at injury sites.[4]
The downstream effect in animal models is faster angiogenesis, increased fibroblast migration, and improved collagen deposition — the cellular machinery of wound healing. Whether these mechanisms operate the same way in humans remains an open question.
What the evidence shows
We separate the evidence by study type because mixing animal data with human case reports and full clinical trials — as much marketing material does — produces a misleading picture of how well-validated this compound actually is.
What experts say
We track positions from clinicians and researchers who have publicly evaluated BPC-157 with attention to the underlying evidence. Quotes are paraphrased to their published positions; original sources are linked.
Places BPC-157 in his evidence framework's lowest tier — biologically plausible but lacking the human evidence needed to recommend.
Describes the situation as unusual — extensive animal data and very widespread use, with essentially no rigorous human trials. Explicitly cautions against use in anyone with active cancer or significant cancer history due to BPC-157's pro-angiogenic effects.
Concludes BPC-157 demonstrates potential benefits in tendon and muscle repair, but notes findings remain largely unvalidated in human trials and methodological flaws limit the existing case series.
Marketed claims vs. published evidence
Vendor sites, social media, and biohacking communities make a wide range of claims about BPC-157. The published human evidence supports a much smaller subset.
Risks, side effects, and contraindications
The risk profile of BPC-157 has two distinct components: pharmacological risks inherent to the compound, and supply chain risks specific to how most users obtain it.
Pharmacological. BPC-157 promotes angiogenesis — the formation of new blood vessels. In healthy tissue this supports repair; in tissue containing a pre-existing tumor it carries a theoretical risk of accelerating tumor vascularization. Andrew Huberman has explicitly cautioned against use in anyone with active cancer or significant cancer history.[8] Long-term human safety data is not available because long-term human studies have not been conducted. Common reported side effects in animal and anecdotal human use include injection site reactions and transient gastrointestinal effects.
Supply chain. A substantial portion of BPC-157 in circulation reaches users through "research use only" suppliers operating outside pharmaceutical quality controls. A 2024 analysis of gray-market peptide products documented significant variability in actual peptide content versus labeled dose, contamination with bacterial endotoxins, and in some cases entirely incorrect compounds in the vial.[9] Compounding pharmacies operating under USP 797/795 standards provide a different and substantially better quality assurance pathway, which is part of why the April 2026 Category 1 reclassification matters clinically.
Access and sourcing
The legal landscape for BPC-157 changed materially in early 2026.
In late 2023, the FDA placed BPC-157 — along with 18 other peptides — on its Category 2 restricted compounding list, effectively preventing licensed 503A compounding pharmacies from preparing it for patients.[10] On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly announced that approximately 14 of those 19 peptides, including BPC-157, would return to Category 1 status. The reclassification became effective April 23, 2026.[11]
What this means in practice: licensed 503A compounding pharmacies can again prepare BPC-157 for individual patients with a valid, patient-specific prescription. The Pharmacy Compounding Advisory Committee will conduct a formal review at its July 23–24, 2026 meeting to determine official compounding eligibility going forward.[11]
What this does not mean: BPC-157 is not an FDA-approved drug. Category 1 status permits compounding while a substance remains under FDA evaluation; it does not constitute approval, does not establish efficacy, and does not change the underlying evidence base.[12] Patients should work with a licensed prescriber and a PCAB-accredited compounding pharmacy rather than sourcing through unregulated channels.
We do not recommend specific vendors on this page. Vendor-related guidance lives in a separate, clearly-labeled section of this site, with a different editorial process and disclosure standards.
Frequently asked
Related peptides
References
- Sikirić P, Seiwerth S, Brčić L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. Current Pharmaceutical Design. 2010. PMID 21443487
- Sikirić P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 — a review. Current Medicinal Chemistry. 2018. PMID 29345570
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017. PMID 27838742
- Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID 25268713
- Krivic A, Anić T, Seiwerth S, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research. 2006. PMID 16937416 Listed as foundational animal evidence frequently cited in human trial rationale.
- Attia P. AMA #83: Peptides — evaluating the science, safety, and hype in a rapidly growing field. The Peter Attia Drive. 2026. ↗ Source podcast
- Author group, JAAOS. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Journal of the American Academy of Orthopaedic Surgeons. 2024. PMID 41476424
- Huberman A. Benefits & risks of peptide therapeutics for physical & mental health. Huberman Lab. 2024. ↗ Source podcast
- Peptide Database editorial. FDA peptide reclassification 2026: which peptides are coming back. peptide-db.com. 2026. ↗ Source industry-analysis
- Beverly Hills Rejuvenation Center editorial. Potential FDA peptide reclassification 2026: what it means for patients. bhrcenter.com. 2026. ↗ Source industry-analysis
- Amanecia Health editorial. FDA peptide reclassification 2026. amaneciahealth.com. 2026. ↗ Source industry-analysis
- OpenLoop Health editorial. What peptides are becoming legal in 2026? openloophealth.com. 2026. ↗ Source industry-analysis
- 2026-05-02Page first published. Reflects April 23, 2026 Category 1 reclassification.